Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proven adenocarcinoma of the prostate~* Stage: cT1c-3b N0M0 according to American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM)~* Prostatic Specific Antigen (PSA)\<100 ng/ml~* Intermediate (T1-T2 with Gleason Score \[GS\] 7 and/or PSA 10-20)~* High risk (T3 and/or GS 8-10 and/or PSA \> 20)~* Karnofsky Index (KI) performance status ≥70%~* Written informed consent~Exclusion Criteria:~* T4 N1 M1,~* Previous surgical treatment (prostatectomy or cryosurgery)~* Neoadjuvant hormonal treatment \> 3 months.~* History of pelvic radiotherapy (RT)~* Contraindications for radiotherapy~* Concomitant use of chemotherapy~* Serious psychiatric or medical condition~* Current synchronic malignancies

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Long term androgen deprivation (Type: EXPERIMENTAL): * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* High dose conformal radiotherapy~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
- Short term androgen deprivation (Type: ACTIVE_COMPARATOR): * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* High dose conformal radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).